CN103073496B - The preparation method of Dextromethorphane Hbr - Google Patents
The preparation method of Dextromethorphane Hbr Download PDFInfo
- Publication number
- CN103073496B CN103073496B CN201310051880.0A CN201310051880A CN103073496B CN 103073496 B CN103073496 B CN 103073496B CN 201310051880 A CN201310051880 A CN 201310051880A CN 103073496 B CN103073496 B CN 103073496B
- Authority
- CN
- China
- Prior art keywords
- dextromethorphane hbr
- preparation
- hours
- reaction
- dextromethorphane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- UPARLEVJTRQMJB-QAPCUYQASA-N CNCC[C@@](CCCC1)([C@H]1CC1)c2c1ccc(OC)c2 Chemical compound CNCC[C@@](CCCC1)([C@H]1CC1)c2c1ccc(OC)c2 UPARLEVJTRQMJB-QAPCUYQASA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Present invention is disclosed the preparation method of a kind of Dextromethorphane Hbr (I), its comprise the steps: with intermediate ent-3-methoxyl group mutter (II) carry out N-methylate generate described Dextromethorphane Hbr (I).This preparation method is simple and convenient, be conducive to the production cost reducing Dextromethorphane Hbr, and can improve the quality of product.
Description
Technical field
The invention belongs to methodology of organic synthesis design and bulk drug and Intermediate Preparation technical field, particularly a kind of preparation method of Dextromethorphane Hbr.
Background technology
Dextromethorphane Hbr ((+)-3-methoxyl group-17-methyl-(9 α, 13 α, 14 α)-mutter, I) be the dextrorotatory isomer of m orphine levo-dromoran methyl ether, central antitussive effect is played by suppressing oblongata coughing centre, be a kind of powerful central antitussive, its antibechic intensity is equal with morphine monomethyl ether or slightly strong.Due to this kind resistance and additive all lower, because of but the antitussive medicine that uses of a kind of applicable long-term taking or high dosage.This medicine is recorded by multinational pharmacopeia, and Ye Shi China needs one of kind given priority in this field.
The preparation of existing Dextromethorphane Hbr is mostly by the following method: optically pure intermediate (+)-1-(4-methoxyl group) benzyl-1, 2, 3, 4, 5, 6, 7, 8-octahydro isoquinoline 99.9 (V), through N-formylation reaction, sodium borohydride reduction, obtain the formylated intermediate (+) of N--1-(4-methoxyl group) benzyl-N-formyl radical-1 successively, 2, 3, 4, 5, 6, 7, 8-octahydro isoquinoline 99.9 (VI) and the methylated intermediate (+) of N--1-(4-methoxyl group) Benzyl-N-methyl-1, 2, 3, 4, 5, 6, 7, 8-octahydro isoquinoline 99.9 (VII), intermediate (VII) obtains intermediate ent-3-hydroxyl-17-methyl through acid catalyzed annulation and mutters (III), intermediate (III) obtains target product Dextromethorphane Hbr by O-methylation reaction again.
The above-mentioned operational path preparing Dextromethorphane Hbr via intermediate (III) solves the Industrialized processing technique of this bulk drug substantially.But, by intermediate (III) prepare Dextromethorphane Hbr carry out O-methylation reaction time, as methyl-sulfate, methyl iodide etc., N-can be there is to some extent and to methylate side reaction, form quaternary ammonium salt by product (VIII) in conventional methylating reagent.So, in actual production process, have to use selectivity good, but the special methylating reagent that price is high, as trimethylphenyl ammonium hydroxide controls the process of side reaction, and carry out in toluene and methanol mixed solvent (see " pharmacy today " 18 volumes the 4th phase in 2008 the 63rd page).Because trimethylphenyl ammonium hydroxide price is higher, and difficult acquisition, methylated yield only has about 50%, thus makes the production cost of Dextromethorphane Hbr significantly improve.More outstanding, the by product DMA of this reaction belongs to genotoxicity material, and its residual quantity will directly affect the quality of bulk drug.At present, the residual control of DMA has been listed among USP, EP, JP and Chinese Pharmacopoeia as a crucial rigid index.So, if another succinct convenient, with low cost and Dextromethorphane Hbr route of nontoxicity residue can be designed, there is important actual application value.
Summary of the invention
The object of the invention is to the defect overcoming prior art, a kind of preparation method of new Dextromethorphane Hbr is provided, this preparation method is simple and convenient, be conducive to reducing the production cost of Dextromethorphane Hbr, and the quality of product can be improved.
To achieve these goals, the present invention adopts following main technical schemes: the preparation method of a kind of Dextromethorphane Hbr (I), it is characterized in that described preparation method comprise the steps: with intermediate ent-3-methoxyl group mutter (II) carry out N-methylate generate described Dextromethorphane Hbr (I).
In addition, the present invention also provides following attached technical scheme:
Described N-methylates and comprises the reduction reaction of N-formylation reaction and methane amide.
Described formylation reagent is formaldehyde, paraformaldehyde, formic acid or alkyl formate.
The alkyl of described alkyl formate is the common allcyl groups that methyl, ethyl, propyl group, sec.-propyl or carbon atom are less than 10.
The solvent of described formylation reaction is methyl alcohol, ethanol, Virahol, methyl-formiate, ethyl formate, methylene dichloride, trichloromethane, toluene, the mixed solvent between dimethylbenzene, water or aforementioned solvents.
The reductive agent of described formamide is sodium borohydride, POTASSIUM BOROHYDRIDE, sodium cyanoborohydride, borine, Lithium Aluminium Hydride or catalytic hydrogenation.
The catalyzer of described catalytic hydrogenation is Raney's nickel, palladium charcoal or palladium hydroxide charcoal.
The solvent of described catalytic hydrogenation is the mixed solvent between methyl alcohol, ethanol, Virahol, water or aforementioned solvents.
Compared to prior art, the preparation method of Dextromethorphane Hbr provided by the present invention, its advantage is mainly muttered by the intermediate ent-3-methoxyl group be easy to get can obtain Dextromethorphane Hbr through the N-preparation that methylates.The method is conducive to reducing the production cost of Dextromethorphane Hbr and improving the quality of product, and the Dextromethorphane Hbr obtained by the method meets or exceeds standards of pharmacopoeia both domestic and external, thus facilitates the economic technology development of this bulk drug.
Embodiment
Foregoing invention is utilized to carry out obtained Dextromethorphane Hbr how simply and easily by being set forth by three concrete preparation process and method below.
Embodiment one: add intermediate (II) (25.7g, 0.1mol), 40% formaldehyde (15.0g, 0.2mol) and methyl alcohol 200mL in 500mL three-necked bottle successively, low rate mixing reacts 12 hours.Reaction solution is proceeded to hydrogenation reaction cauldron, adds Raney's nickel 3g, the gentle 2-4 kilogram of pressure of holding chamber, react 4 hours, TLC detection reaction terminates.Filtering recovering catalyst, mother liquor concentrating under reduced pressure, residuum recrystallizing methanol obtains off-white color solid Dextromethorphane Hbr (I) 22.5g, yield 83.0%.
Embodiment two: add intermediate (II) (25.7g in 500mL three-necked bottle successively, 0.1mol), paraformaldehyde (6.0g, 0.2mol), solid carbonic acid potassium (13.8g, 0.1mol), methyl alcohol 150mL and water 50mL, be warming up to 65-75 DEG C, start stirring reaction 6 hours.Reaction solution is proceeded to hydrogenation reaction cauldron, adds palladium charcoal 3g, be warming up to 40-45 DEG C, keep 2-4 kilogram of pressure, react 6 hours, TLC detection reaction terminates.Filtering recovering catalyst, mother liquor concentrating under reduced pressure, residuum recrystallizing methanol obtains off-white color solid Dextromethorphane Hbr (I) 23.8g, yield 87.8%.
Embodiment three: add intermediate (II) (25.7g in 500mL three-necked bottle successively, 0.1mol), sodium methylate (10.8g, 0.2mol), methyl-formiate 150mL, be warming up to 50-55 DEG C, stirring reaction 6 hours, TLC detection reaction terminates.Removal of solvent under reduced pressure, residue dissolve with ethanol.Add sodium borohydride (4.6g, 0.12mol), fall room temperature reaction 12 hours, TLC detection reaction terminates in batches.Mother liquor concentrations, residue with Ethyl acetate dissolves, and with using dilute hydrochloric acid and water washing to neutral successively, anhydrous sodium sulfate drying.Concentrating under reduced pressure, residuum recrystallizing methanol obtains off-white color solid Dextromethorphane Hbr (I) 21.6g, yield 79.6%.
It is pointed out that above-mentioned preferred embodiment is only and technical conceive of the present invention and feature are described, its object is to person skilled in the art can be understood content of the present invention and implement according to this, can not limit the scope of the invention with this.All equivalences done according to spirit of the present invention change or modify, and all should be encompassed within protection scope of the present invention.
Claims (1)
1. a preparation method for Dextromethorphane Hbr (I),
It is characterized in that described preparation method comprises the steps:
The 0.1mol intermediate (II) of 25.7g, the 0.2mol sodium methylate of 10.8g, 150mL methyl-formiate is added successively in three-necked bottle, be warming up to 50-55 DEG C, stirring reaction 6 hours, TLC detection reaction terminates, removal of solvent under reduced pressure, residue dissolve with ethanol; Add the 0.12mol sodium borohydride of 4.6g, fall room temperature reaction 12 hours, TLC detection reaction terminates in batches; Mother liquor concentrations, residue with Ethyl acetate dissolves, and with using dilute hydrochloric acid and water washing to neutral successively, anhydrous sodium sulfate drying; Concentrating under reduced pressure, residuum recrystallizing methanol obtains off-white color solid Dextromethorphane Hbr (I).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310051880.0A CN103073496B (en) | 2013-02-18 | 2013-02-18 | The preparation method of Dextromethorphane Hbr |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310051880.0A CN103073496B (en) | 2013-02-18 | 2013-02-18 | The preparation method of Dextromethorphane Hbr |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103073496A CN103073496A (en) | 2013-05-01 |
| CN103073496B true CN103073496B (en) | 2015-08-26 |
Family
ID=48150216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310051880.0A Active CN103073496B (en) | 2013-02-18 | 2013-02-18 | The preparation method of Dextromethorphane Hbr |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103073496B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104119273B (en) * | 2014-04-24 | 2017-11-21 | 上海天慈生物谷生物工程有限公司 | A kind of method for preparing dextromethorphan |
| CN106432079A (en) * | 2016-08-31 | 2017-02-22 | 江苏宝众宝达药业有限公司 | Synthesis method of impurity 3-methoxy-17-methylmorphinan-10-one enantiomer of dextromethorphan |
| CN115557891A (en) * | 2022-10-28 | 2023-01-03 | 上海万巷制药有限公司 | Preparation method of dextromethorphan |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3634429A (en) * | 1969-09-30 | 1972-01-11 | Hoffmann La Roche | Morphinan derivatives and preparation thereof |
| US3819635A (en) * | 1971-09-08 | 1974-06-25 | Bristol Myers Co | 14-hydroxymorphinan derivatives |
| EP0834506A1 (en) * | 1996-10-02 | 1998-04-08 | F. Hoffmann-La Roche Ag | Process for the preparation of (9alpha, 13alpha, 14alpha)-1-(3-Methoxymorphinan-17-yl)alkanones |
| HK1076052A1 (en) * | 2002-07-17 | 2006-01-06 | Avanir Pharmaceuticals | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120053169A1 (en) * | 2008-10-30 | 2012-03-01 | Amanda Thomas | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury |
-
2013
- 2013-02-18 CN CN201310051880.0A patent/CN103073496B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3634429A (en) * | 1969-09-30 | 1972-01-11 | Hoffmann La Roche | Morphinan derivatives and preparation thereof |
| US3819635A (en) * | 1971-09-08 | 1974-06-25 | Bristol Myers Co | 14-hydroxymorphinan derivatives |
| EP0834506A1 (en) * | 1996-10-02 | 1998-04-08 | F. Hoffmann-La Roche Ag | Process for the preparation of (9alpha, 13alpha, 14alpha)-1-(3-Methoxymorphinan-17-yl)alkanones |
| HK1076052A1 (en) * | 2002-07-17 | 2006-01-06 | Avanir Pharmaceuticals | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103073496A (en) | 2013-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2322486T5 (en) | Preparation of opioid analgesics by reductive alkylation | |
| CN103113378B (en) | A kind of synthetic method of oxymorphone hydrochloride | |
| CN103073496B (en) | The preparation method of Dextromethorphane Hbr | |
| CN106458853B (en) | Method for preparing sitagliptin intermediate by asymmetric reduction method | |
| WO2022222914A1 (en) | Preparation method of l-nicotine | |
| CN103351372A (en) | Preparation method of ticagrelor intermediate | |
| CN101973911A (en) | Method for synthesizing anastrozole intermediate-2,2'-(5-methyl-1,3-phenylene)-bis-(2-methyl propionitrile) | |
| CN102898372B (en) | Preparation method of dextromethorphan | |
| CN103012268B (en) | Novel preparation method for ivabradine | |
| CN103497157B (en) | 2-imidazolidone synthesis method | |
| CN102070526B (en) | Method for synthesizing 3-aza-bicyclo[4.1.0]heptane-6-formic acid with protective group | |
| CN103896795B (en) | The preparation method and its usage of benzamide compound, its intermediate | |
| CN103319356A (en) | One-step green synthesis process of antimalarial raw material benflumetol | |
| CN103739545B (en) | Simple preparation method of vitamin B6 | |
| CN102936216B (en) | Preparation method of 7,9-dioxo-2,6-aza-spiro[3.5]nona-2-tert-butyl formate and intermediate thereof | |
| CN101891692A (en) | Preparation method of homopiperazine | |
| CN101475491B (en) | N-substituted 1,2-diphenylethylamine compounds and synthesizing method thereof | |
| CN103554019B (en) | A kind of synthetic method of tilbroquinol | |
| CN110218189A (en) | A kind of simple and convenient process for preparing of Abbe Seeley intermediate and Abbe Seeley | |
| CN105418489A (en) | Synthesis method of bupivacaine | |
| CN103044327A (en) | Preparation method of dextromethorphan | |
| CN103073495B (en) | The preparation method that a kind of ent-3-methoxyl group is muttered | |
| CN106749116A (en) | A kind of preparation method of 3 amino methyl tetrahydrofuran | |
| CN102976959B (en) | Preparation method of ritodrine | |
| CN108976182A (en) | A method of preparing Dapagliflozin five-membered ring impurity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200709 Address after: Hu Suzhou high tech Zone of Jiangsu province 215151 City Road No. 21 Tang Guan District Patentee after: SUZHOU LIXIN PHARMACEUTICAL Co.,Ltd. Address before: 215151 No. 21 West Tong Road, hi tech Development Zone, Jiangsu, Suzhou Co-patentee before: Xu Xuenong Patentee before: SUZHOU LIXIN PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right |